Stock Events

Newron Pharmaceuticals Spa. 

€9.3
0
+€0+0% Friday 16:30

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
151.69M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MarExpected
Q4 2015
Q2 2016
Q4 2016
Q2 2017
Q4 2017
Q2 2022
Next
-1.13
-0.72
-0.32
0.09
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NP5.XETRA. It's not an investment recommendation.

About

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
Show more...
CEO
Mr. Stefan Weber
Employees
23
Country
IT
ISIN
IT0004147952
WKN
000A0LF18

Listings